(TCRT) Alaunos Therapeutics, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TCRT) Alaunos Therapeutics, Inc. Complete Analysis Pack
Alaunos Therapeutics Business Model Canvas at a Glance
Unlock the full strategic blueprint behind Alaunos Therapeutics, Inc.’s business model. This concise Business Model Canvas highlights how the company creates value, manages key partnerships, and positions itself in a fast-moving biotech landscape. Ideal for investors, analysts, and strategists who want actionable insight—get the full version to see every building block in detail.
Partnerships
PGEN Therapeutics licensing agreement
Alaunos Therapeutics, Inc. uses its licensing agreement with PGEN Therapeutics, Inc. to access outside IP and technology that supports its TCR-engineering and cell-therapy work. This partnership helps Alaunos broaden its R&D base without building every core tool in-house, which is important for a company still focused on platform development.
MD Anderson Cancer Center R&D partnership
Alaunos Therapeutics, Inc. partners with The University of Texas MD Anderson Cancer Center, a leading oncology research hub with more than 1,800 faculty and over 1,300 active clinical trials, to advance translational research in solid tumors. The tie-up helps Alaunos de-risk early development and speed clinical proof-of-concept work.
National Cancer Institute patent licensing
Alaunos Therapeutics, Inc. has a patent licensing and R&D agreement with the National Cancer Institute, giving it federal research support and access to NCI intellectual property for TCR discovery and validation. This partnership helps de-risk early-stage work and strengthen the company’s cell-therapy platform, which is vital for a company with limited operating scale and a market cap that has been well below $100 million in recent filings.
Clinical trial investigators
Alaunos Therapeutics, Inc. relies on physician investigators to run its Phase I/II trials, where they screen patients, administer protocols, and collect safety and efficacy data. In early-stage oncology studies, this role is critical because human evidence from small cohorts drives go/no-go calls on each program.
- Run Phase I/II trial sites
- Screen and enroll patients
- Capture safety and response data
- Support human proof-of-concept
Manufacturing and research ecosystem
Alaunos Therapeutics, Inc. depends on external research and manufacturing partners to build engineered T-cell therapies, since these programs need GMP lab work, process development, and release testing before clinical use. In 2025, the company stayed a small, precommercial cell-therapy developer, so outside CDMOs and CROs are key to moving candidates from discovery into trials.
- Uses outside GMP and QC support
- Relies on CROs for trial prep
Alaunos leans on powerhouse partners to advance cell therapy
Alaunos Therapeutics, Inc. depends on outside partners for IP, research, trials, and GMP work. Key ties include PGEN Therapeutics, Inc., The University of Texas MD Anderson Cancer Center, the National Cancer Institute, physician investigators, and CRO/CDMO vendors.
MD Anderson adds scale with more than 1,800 faculty and over 1,300 active clinical trials, while Alaunos Therapeutics, Inc. stays a small precommercial cell-therapy developer with a market cap below $100 million in recent filings.
| Partner | Role |
|---|---|
| MD Anderson | Translational trials |
| NCI | IP and research support |
What is included in the product
Detailed Word Document
A concise, real-world BMC for Alaunos Therapeutics, showing its cell-therapy biotech model, partners, value proposition, channels, and key risks.
Customizable Excel Spreadsheet
Helps quickly map Alaunos Therapeutics’ business model pain points in a clear, editable one-page format.
Reference Sources
Provides a traceable source trail that strengthens Alaunos Therapeutics, Inc. claims and speeds investor due diligence.
Activities
TCR library development
Alaunos Therapeutics, Inc. is building a TCR library with 10 T-cell receptors, targeting mutated KRAS, TP53, and EGFR. This is a core discovery engine for its solid-tumor cell therapy work, focused on finding tumor-specific targets that can support future clinical candidates.
Phase I/II clinical trials
Alaunos Therapeutics, Inc. is advancing Phase I/II trials to test TCR-T therapies in solid tumors, including non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Trial execution is the key activity to prove safety and early efficacy, with each study designed to refine dose, response rates, and patient selection across these hard-to-treat cancers.
Neoantigen receptor discovery
Alaunos Therapeutics, Inc. uses hunTR to find human T-cell receptors that bind tumor-specific neoantigens, aiming to lift precision targeting beyond known mutations. This discovery work matters because neoantigens are often unique to each tumor, so one validated receptor can open a highly selective treatment path for a new patient set.
mbIL-15 platform development
Alaunos Therapeutics, Inc. is developing the mbIL-15 platform for solid tumors, aiming to boost anti-tumor immune activity inside a setting that represents about 90% of adult cancers. It sits inside the company’s engineered T-cell strategy, which is built to improve the weak response rates seen in many solid-tumor cell therapies.
- Targets solid tumors, 90% of adult cancers
- Designed to raise anti-tumor immune activity
- Core part of engineered T-cell strategy
Regulatory and IP management
Alaunos Therapeutics must tightly manage patents, licenses, and FDA trial rules because its value sits in a platform, not a product. In 2025, the company still had no commercial revenue, so trial oversight, clean documentation, and IP protection stay central to keeping its cell-therapy know-how defensible.
Protect patents and licensed tech.
Track trial documents and compliance.
Guard platform IP as core value.
Alaunos 2025: TCR Pipeline, 6 Cancers, Zero Revenue
Alaunos Therapeutics, Inc.'s key activities are TCR discovery, solid-tumor cell therapy development, and clinical trial execution across NSCLC, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. In 2025, the Company still had no commercial revenue, so IP protection, FDA compliance, and trial data generation remained the main operating work.
| Key activity | 2025 data |
|---|---|
| TCR library | 10 T-cell receptors |
| Clinical scope | 6 solid-tumor indications |
| Commercial revenue | $0 |
Delivered as Displayed
Business Model Canvas
This Alaunos Therapeutics, Inc. Business Model Canvas preview is the exact document you’ll receive after purchase, not a sample or placeholder. What you see here is a live snapshot of the final file, with the same structure, content, and formatting. Once you complete your purchase, you’ll unlock the full version of this same ready-to-use document for immediate download.
Resources
10 TCR library
Alaunos Therapeutics’ 10 TCR library is its core scientific asset: ten engineered T-cell receptors built to target key cancer mutations. That focused panel gives the company a narrow but high-value base for its cell therapy strategy, with each receptor aimed at a specific tumor antigen.
KRAS TP53 EGFR targets
Alaunos Therapeutics, Inc. focuses its platform on mutated KRAS, TP53, and EGFR, three high-value solid-tumor targets. KRAS mutations appear in about 25% of human cancers, TP53 is altered in more than 50% of tumors, and EGFR mutations drive about 10% to 15% of non-small cell lung cancer, making target choice a key edge.
hunTR platform
hunTR is Alaunos Therapeutics, Inc.’s platform for human neoantigen T-cell receptors, and it broadens the company’s discovery engine beyond a single program. By feeding new TCR candidates into the pipeline, it gives Alaunos Therapeutics, Inc. a path to future growth as it builds more shots on goal.
mbIL-15 platform
mbIL-15 is one of Alaunos Therapeutics, Inc.'s core development assets, designed to improve T-cell persistence and activity in solid tumors. It broadens the Company’s therapeutic toolkit by adding a platform aimed at tougher, high-unmet-need cancers.
- Core solid-tumor resource
- Expands cell-therapy tools
- Targets T-cell persistence
Clinical and IP agreements
Alaunos Therapeutics, Inc. relies on 3 core clinical and IP agreements with PGEN, MD Anderson, and the NCI. These deals give it access to research data, know-how, and licensed intellectual property, which is vital for a clinical-stage biotech that depends on outside science more than large in-house labs.
- 3 key licensing and R&D agreements
- Access to data, know-how, and IP
- Core resource for clinical-stage development
Alaunos’ Core Assets Power a Focused Solid-Tumor Cell Therapy Strategy
Alaunos Therapeutics, Inc.’s key resources are its 10 TCR library, hunTR discovery platform, mbIL-15 program, and three core PGEN, MD Anderson, and NCI agreements. Together, they support a focused solid-tumor cell therapy strategy built on licensed IP, research access, and engineered T-cell assets.
| Resource | Use |
|---|---|
| 10 TCR library | Core tumor-targeting asset |
| hunTR | Neoantigen discovery engine |
| 3 agreements | IP, data, know-how access |
Value Propositions
Engineered TCR therapies
Alaunos Therapeutics develops adoptive T-cell receptor engineered therapies that target cancer-specific mutations, aiming at intracellular neoantigens that most antibodies miss. In solid tumors, which account for about 90% of cancers, this precision approach is meant to improve selectivity over broad chemotherapy.
Solid tumor targeting
Alaunos Therapeutics focuses on solid tumors with major unmet need, including non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. In 2025, the American Cancer Society estimated about 2.0 million new U.S. cancer cases and 618,120 deaths, underscoring the scale of this market and the broad oncology reach of its platform.
Mutation-specific precision
Alaunos Therapeutics, Inc. focuses on mutated KRAS, TP53, and EGFR, three drivers found in many hard-to-treat tumors; KRAS mutations appear in about 90% of pancreatic ductal adenocarcinoma, 40% of colorectal cancer, and 25% of lung adenocarcinoma cases. Mutation-specific targeting can lift selectivity versus non-specific therapy, aiming to spare more healthy tissue.
Neoantigen discovery capability
hunTR is designed to identify human neoantigen T-cell receptors, giving Alaunos Therapeutics, Inc. a deeper way to find targets for highly personalized immunotherapy. That discovery layer can widen its platform beyond standard screening and improve the chance of matching tumors with patient-specific T-cell therapies.
- hunTR maps human neoantigen TCRs
- Supports personalized immunotherapy
- Adds discovery depth to the platform
Multiple-stage pipeline
Alaunos Therapeutics, Inc. spreads risk across the TCR Library, hunTR, and mbIL-15 platforms, so it has multiple shots on goal instead of relying on one asset. That matters in cell therapy, where pipeline attrition is high; three active platform bets can improve the chance that at least one program reaches a value-creating milestone.
- Three platforms, not one
- Reduces single-asset risk
- More paths to clinical proof
Alaunos Targets Hard-to-Treat Cancers with Precision T-Cell Therapies
Alaunos Therapeutics, Inc. offers mutation-specific T-cell receptor therapies for hard-to-treat solid tumors, aiming at intracellular neoantigens that standard antibodies miss. Its value lies in precision targeting of KRAS, TP53, and EGFR, plus a discovery stack that can feed more personalized programs.
| Value driver | Data point |
|---|---|
| U.S. cancer burden | 2.0M new cases, 618,120 deaths in 2025 |
| KRAS prevalence | ~90% pancreatic, 40% colorectal, 25% lung adenocarcinoma |
Customer Relationships
Clinical investigator collaboration
Alaunos Therapeutics, Inc. works closely with oncology investigators to run trials, keep protocols on track, and monitor patients. In recent filings, the Company reported no product revenue, so these investigator ties are key to generating credible clinical data and advancing each study with limited capital.
Academic research partnership model
Alaunos Therapeutics, Inc. builds its academic research partnership model through institutions like MD Anderson Cancer Center, which helps align shared research goals and give early oncology ideas scientific validation. For an early-stage cell therapy company, this kind of relationship is key: in 2025, its value comes less from volume and more from a small number of high-trust research anchors.
Regulated patient interaction
Alaunos Therapeutics, Inc. keeps patient contact tightly regulated: trial sites handle outreach, consent, and follow-up, and every message must fit clinical and ethics rules. As a Phase I/II biotech, it is still pre-commercial, so patient relationships are built around protocol compliance, safety monitoring, and documented informed consent rather than direct marketing.
Partner-facing technical support
Alaunos Therapeutics, Inc. depends on partner-facing technical support to keep licensing and research ties active, with regular data sharing, reporting, and joint planning at the center of the model. This kind of collaboration is critical when the business has limited operating scale and must keep each partner program moving with clear technical updates.
- Frequent data exchange
- Joint development planning
- Technical reporting discipline
Scientific community engagement
Alaunos Therapeutics, Inc. likely uses ASCO-style oncology forums, peer-reviewed publications, and conference posters to build trust with researchers and clinicians; for a clinical-stage biotech, even 0 product revenue makes scientific credibility a core relationship tool. These touchpoints also keep trial awareness high and can support future trial-site and research partnerships.
- Builds credibility with oncology experts
- Supports trial awareness and partnerships
Alaunos Relies on Trusted Trial Partners, Not Revenue
Alaunos Therapeutics, Inc. keeps customer ties concentrated in a few high-trust channels: oncology investigators, academic centers, and trial sites. In 2025, the Company reported 0 product revenue, so these relationships mainly support protocol execution, data quality, and clinical credibility.
| 2025 metric | Read on relationships |
|---|---|
| 0 product revenue | Pre-commercial, trial-led model |
| Academic partners | Trust anchor for research |
Channels
Clinical trial sites
Alaunos Therapeutics, Inc. reaches patients through clinical trial sites, which are the main channel for enrolling participants and delivering investigational therapy. In Phase I/II development, these sites handle the small, safety-first cohorts that determine whether a cell therapy can move forward.
Academic medical centers
Academic medical centers are Alaunos Therapeutics, Inc.’s main study-execution channel, because they bring oncology specialists and large pools of eligible patients. MD Anderson, which sees more than 174,000 patients a year, is a key network site for enrolling and running complex cell-therapy studies.
Investigator networks
Oncology investigator networks are a key channel for Alaunos Therapeutics, Inc. because they connect the Company to clinical populations and help find patients with the right mutation and tumor type. With about 1.9 million new U.S. cancer cases projected for 2025, referrals from these sites matter most in rare, targeted studies where each eligible patient can move enrollment.
Scientific conferences
Alaunos Therapeutics, Inc. can use scientific conferences to share pipeline updates, trial data, and biomarker results with researchers, clinicians, and potential partners. Major oncology meetings draw tens of thousands of attendees, so this channel gives Alaunos Therapeutics, Inc. high visibility in a science-led market where peer review and KOL trust matter.
- Reaches researchers and clinicians
- Supports partner scouting
- Boosts credibility with data
Corporate partnership outreach
Corporate partnership outreach is a key channel for Alaunos Therapeutics, Inc. because licensing and R&D partnerships can validate the platform and create future monetization paths. These deals are usually built through business development and scientific networking, where shared data, milestone payments, and co-development rights can turn early research into non-dilutive cash flow.
- Builds platform validation
- Opens licensing revenue
- Supports R&D co-development
Alaunos’ Growth Hinges on High-Volume Oncology Channels
Alaunos Therapeutics, Inc. mainly uses trial sites, academic cancer centers, investigator networks, conferences, and partnership outreach to find eligible patients, share data, and win R&D partners. MD Anderson sees more than 174,000 patients a year, and about 1.9 million new U.S. cancer cases are projected for 2025, so access to high-volume oncology channels matters.
| Channel | Data point |
|---|---|
| Academic sites | MD Anderson: 174,000+ patients/year |
| Patient flow | U.S. cancer cases: 1.9M in 2025 |
Customer Segments
Advanced solid tumor patients
Alaunos Therapeutics, Inc. targets advanced solid tumor patients in its clinical trials, with focus on non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. These cancers account for a large share of the 20 million new global cancer cases reported in 2022, and they form the company’s core clinical end-user group.
Mutation-defined oncology patients
Alaunos Therapeutics, Inc. targets mutation-defined oncology patients with KRAS, TP53, and EGFR alterations, so the customer segment is set by tumor genetics, not just tumor type. That matters because KRAS mutations appear in about 25% of cancers, TP53 in more than 50%, and EGFR in roughly 10% to 15% of non-small cell lung cancer cases.
Oncology investigators
Oncology investigators are Alaunos Therapeutics, Inc.'s core customer segment because physician-scientists run the protocols, judge responses, and keep trials credible. Their buy-in drives site activation and enrollment speed, and in oncology trials where per-patient costs can run into the six-figure range, even small delays can hit data quality and cash use fast.
Academic cancer centers
Academic cancer centers are a core institutional customer for Alaunos Therapeutics, Inc. They host investigator-led studies, add translational expertise, and are the best fit for early-stage cell therapy work where access to patients, labs, and KOLs matters most.
These centers also anchor first-in-human and proof-of-concept trials, which is why they shape trial design, site activation, and data generation in a capital-light model.
- Early-stage cell therapy trials
- Translational research support
- Investigator-led study hubs
Biotech and pharma partners
Alaunos Therapeutics, Inc. can target biotech and pharma partners that want TCR discovery or licensing rights. The platform matters because oncology deal flow stayed active in 2025, with partnership-heavy pipelines still a key way to source novel assets.
This is a future commercial segment for Alaunos Therapeutics, Inc., especially for firms that want to add oncology programs without building discovery from scratch.
- TCR discovery and licensing
- Oncology asset access
- Future partner revenue
Alaunos Targets a Massive Mutation-Driven Cancer Market
Alaunos Therapeutics, Inc. serves three main customer sets: mutation-defined advanced solid tumor patients, oncology investigators at academic cancer centers, and future biotech or pharma partners. Its patient pool is large, with about 20 million new cancer cases worldwide in 2022 and KRAS mutations in about 25% of cancers, while EGFR changes show up in roughly 10% to 15% of non-small cell lung cancers.
| Segment | Why it matters |
|---|---|
| Patients | Clinical trial enrollment |
| Academia | Site activation and data |
| Partners | TCR licensing and access |
Cost Structure
Clinical trial expense
For Alaunos Therapeutics, Inc., clinical trial expense is a major cost driver because Phase I/II cell therapy studies are resource intensive. Industry data put Phase I trials at about $4 million on average and Phase II at about $13 million, with costs rising from site fees, monitoring, data capture, and intensive patient management.
R&D personnel and lab spend
R&D personnel and lab spend is a core fixed cost for Alaunos Therapeutics, Inc., because TCR discovery and platform work need scientists, clinicians, and technical staff plus constant lab inputs. In its latest filings, Alaunos Therapeutics, Inc. has kept R&D lean as it protects cash, but this line item still drives the science engine and scales fast if programs restart or expand.
Manufacturing and process development
Engineered T-cell therapies need custom cell processing, viral vector work, and tight quality checks, so manufacturing and process development stay heavy cost items. For Alaunos Therapeutics, Inc., this burden rises as programs move from lab work into clinical use, while the company still reported no product revenue in 2025, so these costs sit mainly in R&D and supply-chain support.
Licensing and IP costs
Alaunos Therapeutics, Inc. must keep paying patent, licensing, and agreement costs, plus outside legal support for IP filings and contract work. For a cell-therapy biotech, protecting know-how is core value protection, because a single patent family can take years to secure and maintain.
- Patent and filing fees
- License and access payments
- Legal support costs
- IP defense is strategic
General and administrative overhead
Alaunos Therapeutics, Inc. keeps general and administrative overhead tied to its Houston base, where headquarters, corporate admin, and compliance sit. As a public company, it also must fund SEC reporting, audit, legal, board, and governance costs, which stay fixed even when revenue is minimal.
- Houston headquarters drives base overhead.
- SEC reporting adds recurring cost.
- Board, audit, and legal fees persist.
Alaunos’ 2025 Costs: R&D Heavy, No Product Revenue
Alaunos Therapeutics, Inc. cost structure is dominated by R&D, especially clinical trials, lab staff, and manufacturing development; in 2025 it still had no product revenue, so these costs stayed precommercial. G&A also stays fixed through SEC reporting, audit, legal, and board support.
| Cost item | 2025 detail |
|---|---|
| Clinical trials | Major R&D spend |
| R&D staff and labs | Core fixed cost |
| G&A | Public company overhead |
| Revenue | $0 product revenue |
Revenue Streams
Licensing agreements
Alaunos Therapeutics, Inc. can generate revenue from licensing agreements that may pay upfront fees, development milestones, and royalties, which is a common biotech monetization path before product approval. Its latest 2025/2026 deal terms and cash amounts are not disclosed here, so the stream should be viewed as potential IP-based income rather than product sales.
Collaboration payments
For Alaunos Therapeutics, Inc., collaboration payments can come from sponsored R&D or shared development deals, and that matters because the Company had no product revenue in its 2025 filings. For a clinical-stage biotech, even modest partner funding can help cover trial spend and reduce dilution.
Milestone receipts
Alaunos Therapeutics, Inc. can earn milestone receipts only when a partner pushes a program past set technical, clinical, or regulatory gates, such as IND filing, first-patient dosing, or Phase 2 readouts. In its latest filed results, the Company did not report milestone revenue, so this stream is still contingent rather than recurring.
Potential future product sales
If Alaunos Therapeutics, Inc. secures approval, product sales could become a future revenue stream, but it has no approved therapy today, so this is not a near-term driver. As a clinical-stage company, the upside is long term and depends on moving from trials to commercialization.
- No current product sales
- Approval would unlock revenue
- Commercial upside is long term
Research support funding
Research support funding can add small, non-dilutive cash inflows for Alaunos Therapeutics, Inc., mainly through academic grants or sponsored studies that help cover early development costs. In biotech, these awards are often modest versus burn: NIH extramural funding was about $35 billion in fiscal 2025, and awards can offset lab, assay, and trial-prep spend.
Non-dilutive cash, not core revenue
Best for early-stage R&D costs
Usually grant-sized, not recurring
Alaunos Has No Product Revenue—Funding Hinges on Grants and Partnerships
Alaunos Therapeutics, Inc. had no product revenue in its 2025 filings, so Revenue Streams still depend on partner cash, grants, and any future licensing or milestone payments. Product sales stay out of scope until the Company has an approved therapy.
In practice, that makes non-dilutive funding the main near-term source, while licensing and milestones remain contingent on clinical or regulatory progress.
| Stream | Status | 2025/2026 |
|---|---|---|
| Product sales | None | 0 |
| Licensing | Potential | Undisclosed |
| Grants | Possible | Non-dilutive |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.